Regeneron

YTD

ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.

CEO

Leonard S. Schleifer

CEOLeonard S. Schleifer

Employees

15,410

Employees15,410

Headquarters

Tarrytown, New York

HeadquartersTarrytown, New York

Founded

1988

Founded1988

Employees

15,410

Employees15,410

REGN Key Statistics

Market cap

73.26B

Market cap73.26B

Price-Earnings ratio

17.01

Price-Earnings ratio17.01

Dividend yield

0.51%

Dividend yield0.51%

Average volume

772.73K

Average volume772.73K

High today

$717.89

High today$717.89

Low today

$693.70

Low today$693.70

Open price

$711.09

Open price$711.09

Volume

728.23K

Volume728.23K

52 Week high

$821.11

52 Week high$821.11

52 Week low

$476.49

52 Week low$476.49

Stock Snapshot

With a market cap of 73.26B, Regeneron(REGN) trades at $697.15. The stock has a price-to-earnings ratio of 17.01 and currently yields dividends of 51.3%.

As of 2026-05-16, Regeneron(REGN) stock has fluctuated between $693.70 and $717.89. The current price stands at $697.15, placing the stock +0.5% above today's low and -2.9% off the high.

Regeneron(REGN) shares are trading with a volume of 728.23K, against a daily average of 772.73K.

In the last year, Regeneron(REGN) shares hit a 52-week high of $821.11 and a 52-week low of $476.49.

REGN News

MarketWatch 22h

Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

...

TipRanks 1d

Real-World Dupixent Data in Canada: What Regeneron and Sanofi Investors Should Watch

Regeneron Pharmaceuticals (REGN), Sanofi (SNYNF) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools...

Simply Wall St 1d

Should First FDA-Approved Gene Therapy for Genetic Hearing Loss Require Action From Regeneron Pharmaceuticals Investors?

Earlier this month, Regeneron Pharmaceuticals received U.S. Food and Drug Administration approval for Otarmeni, the first gene therapy for genetic hearing loss...

Analyst ratings

80%

of 30 ratings

Buy

80%

Hold

20%

Sell

More REGN News

Simply Wall St 7d

A Look At Regeneron Pharmaceuticals Valuation After Otarmeni’s Accelerated FDA Approval

Advertisement How Otarmeni’s approval fits into the Regeneron Pharmaceuticals (REGN) story The FDA’s accelerated approval of Otarmeni, the first gene therapy...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

abrdn Physical Precious M…

Cipher Mining

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.